Neuralstem (NASDAQ: CUR) and Catalent (NYSE:CTLT) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, profitability, institutional ownership, earnings and risk.
Earnings and Valuation
This table compares Neuralstem and Catalent’s gross revenue, earnings per share and valuation.
||Earnings Per Share
Catalent has higher revenue and earnings than Neuralstem. Neuralstem is trading at a lower price-to-earnings ratio than Catalent, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Neuralstem has a beta of 1.54, suggesting that its stock price is 54% more volatile than the S&P 500. Comparatively, Catalent has a beta of 1.47, suggesting that its stock price is 47% more volatile than the S&P 500.
This table compares Neuralstem and Catalent’s net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
This is a summary of current recommendations for Neuralstem and Catalent, as reported by MarketBeat.com.
||Strong Buy Ratings
Neuralstem presently has a consensus target price of $1.91, suggesting a potential upside of 15.76%. Catalent has a consensus target price of $44.67, suggesting a potential downside of 4.15%. Given Neuralstem’s higher possible upside, analysts plainly believe Neuralstem is more favorable than Catalent.
Insider & Institutional Ownership
7.1% of Neuralstem shares are owned by institutional investors. Comparatively, 98.9% of Catalent shares are owned by institutional investors. 19.3% of Neuralstem shares are owned by company insiders. Comparatively, 1.7% of Catalent shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Catalent beats Neuralstem on 9 of the 13 factors compared between the two stocks.
Neuralstem, Inc. (Neuralstem) is a clinical-stage biopharmaceutical company. The Company is engaged in research, development and commercialization of central nervous system therapies based on its human neuronal stem cells and its stem-cell derived small molecule compounds. The Company has approximately three assets: its NSI-189 small molecule program, its NSI-566 stem cell therapy program and its chemical entity screening platform. The Company’s technology allows the commercial-scale production of multiple types of central nervous system stem cells, which are under development for the treatment of central nervous system diseases and conditions. The Company is developing NSI-189 for the treatment of major depressive disorder (MDD) and other psychiatric and/or cognitive impairment indications associated with hippocampal atrophy. The Company’s NSI-566 is indicated for amyotrophic lateral sclerosis (ALS), chronic spinal cord injury and motor deficits due to ischemic stroke.
Catalent, Inc. provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels. The Drug Delivery Solutions segment is engaged in the formulation, development and manufacturing of prescription and consumer and animal health products; blow-fill seal unit dose manufacturing; biologic cell line development; analytical and bioanalytical development, and testing services. The Clinical Supply Services segment is engaged in manufacturing, packaging, labeling, storage, distribution and inventory management for clinical trials of drugs and biologics for patient kits; FastChain clinical supply service; clinical e-solutions and informatics, and global comparator sourcing services.
Receive News & Ratings for Neuralstem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuralstem and related companies with MarketBeat.com's FREE daily email newsletter.